We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MPLX LP (MPLX) Q1 Earnings Beat, Revenues Miss Estimates
Read MoreHide Full Article
Earnings Beat: MPLX LP (MPLX - Free Report) reported first quarter adjusted earnings of 61 cents per unit, beating the Zacks Consensus Estimate of 59 cents.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate of earnings for the quarter has seen no movement in the last seven days.
Before posting Q1 earnings, MPLX LP delivered positive surprises in two of the prior four quarters. Overall, the partnership has an average positive earnings surprise of 6.3% in the trailing four quarters.
Check back later for our full write up on this MPLX LP earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
MPLX LP (MPLX) Q1 Earnings Beat, Revenues Miss Estimates
Earnings Beat: MPLX LP (MPLX - Free Report) reported first quarter adjusted earnings of 61 cents per unit, beating the Zacks Consensus Estimate of 59 cents.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate of earnings for the quarter has seen no movement in the last seven days.
Before posting Q1 earnings, MPLX LP delivered positive surprises in two of the prior four quarters. Overall, the partnership has an average positive earnings surprise of 6.3% in the trailing four quarters.
MPLX LP Price and EPS Surprise
MPLX LP Price and EPS Surprise | MPLX LP Quote
Revenues Miss: MPLX LP posted revenues of $1,646 million, missing the Zacks Consensus Estimate of $1,658 million.
Key Stats: MPLX’s operating income from Logistics and Supply segment witnessed a jump of 25% from the prior-year quarter to $480 million.
Operating income from Gathering and Processing segment increased to $198 million from $172 million in the prior-year quarter.
Zacks Rank: Currently, MPLX LP carries a Zacks Rank #4 (Sell) which is subject to change following the earnings announcement.
(You can see the complete list of today’s Zacks #1 Rank stocks here.)
Check back later for our full write up on this MPLX LP earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>